EGFR and non-small cell lung carcinoma: The discovery of somatic mutations in epidermal growth factor receptor (EGFR) and EGFR tyrosine kinase inhibitors (TKIs) has dramatically improved the survival of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations1–3.